MiR-22 Inhibition Alleviates Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy by Targeting the sirt1/PGC-1α Pathway.
Wang R, Xu Y, Niu X, Fang Y, Guo D, Chen J, Zhu H, Dong J, Zhao R, Wang Y, Qi B, Ren G, Li X, Liu L, Zhang M.
Wang R, et al. Among authors: zhao r.
Front Physiol. 2021 Apr 1;12:646903. doi: 10.3389/fphys.2021.646903. eCollection 2021.
Front Physiol. 2021.
PMID: 33868015
Free PMC article.
Retracted.